ReviewCurrent psychiatry reports2012
Antipsychotic agents in the treatment of anorexia nervosa: neuropsychopharmacologic rationale and evidence from controlled trials.
Review in Current psychiatry reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 49 citations in OpenAlex.
- The integrated treatment of eating disorders, posttraumatic stress disorder, and psychiatric comorbidity: a commentary on the evolution of principles and guidelines.Frontiers in psychiatry · 2023Review
- Headache, eating disorders, PTSD, and comorbidity: implications for assessment and treatment.Eating and weight disorders : EWD · 2022Article
- Adjunctive Clotiapine for the Management of Delusions in Two Adolescents with Anorexia Nervosa.Behavioral sciences (Basel, Switzerland) · 2021Article
- Timing of Psychopharmacological and Nutritional Interventions in the Inpatient Treatment of Anorexia Nervosa: An Observational Study.Brain sciences · 2021Article
- Neuroimaging Findings in Adolescents and Young Adults with Anorexia Nervosa: A Systematic Review.Children (Basel, Switzerland) · 2021Review
- Medication in AN: A Multidisciplinary Overview of Meta-Analyses and Systematic Reviews.Journal of clinical medicine · 2019Review
- Toward A Greater Understanding of the Ways Family-Based Treatment Addresses the Full Range of Psychopathology of Adolescent Anorexia Nervosa.Frontiers in psychiatry · 2019Article
- Investigation of common, low-frequency and rare genome-wide variation in anorexia nervosa.Molecular psychiatry · 2018Article
- Melanin-concentrating hormone is necessary for olanzapine-inhibited locomotor activity in male mice.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2015Article
- Neurobiologically informed treatment for adults with anorexia nervosa: a novel approach to a chronic disorder.Dialogues in clinical neuroscience · 2015Article
- Psychopharmacologic treatment of eating disorders: emerging findings.Current psychiatry reports · 2015Review
- The use of animal models to decipher physiological and neurobiological alterations of anorexia nervosa patients.Frontiers in endocrinology · 2015Review
- Pharmacological manipulations in animal models of anorexia and binge eating in relation to humans.British journal of pharmacology · 2014Review
- Could dopamine agonists aid in drug development for anorexia nervosa?Frontiers in nutrition · 2014Review
- Is deep brain stimulation a treatment option for anorexia nervosa?BMC psychiatry · 2013Review
- Tandospirone, a 5-HT1A partial agonist is effective in treating anorexia nervosa: a case series.Annals of general psychiatry · 2013Article
- Nothing tastes as good as skinny feels: the neurobiology of anorexia nervosa.Trends in neurosciences · 2013Review
- Eating disorders: some new answers to old questions.Current psychiatry reports · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The search for an effective psychopharmacologic strategy in the treatment of anorexia nervosa (AN) has been elusive for decades and has run the gamut from reserpine to typical antipsychotics, to lithium, to tetrahydrocannabinol, to growth hormone, to anticonvulsants, to antidepressants, to atypical antipsychotics. Only recently has there arisen a potential "diamond in the rough" in the form of the atypical antipsychotic agent, olanzapine, which, in four randomized clinical trials, has shown superiority to placebo (two studies), chlorpromazine (one study), and aripiprazole (one study) in terms of weight gain and/or reduction in obsessional symptoms. The pharmacologic profile of olanzapine and other antipsychotic medications is discussed in light of the known pathophysiology of AN involving serotonin and dopamine systems, as well as brain-derived neurotrophic factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.